Who makes ruxolitinib?

Who currently manufactures ruxolitinib?

Incyte Corporation holds the original development and manufacturing rights for ruxolitinib. Incyte developed the active ingredient and owns the brand-name tablets sold as Jakafi in the United States.

How does Incyte license ruxolitinib to other companies?

Incyte has granted Novartis exclusive rights to develop and sell ruxolitinib outside the United States and Canada. Novartis markets the drug under the brand Jakavi in most international markets.

What are the emerging ruxolitinib suppliers?

Several Indian manufacturers now produce generic versions of ruxolitinib after key patents began expiring. Companies such as Hetero Labs, Natco Pharma, and Sun Pharma Advanced Research Company have filed abbreviated new drug applications or announced launches.

When does the ruxolitinib patent expire?

The primary composition-of-matter patent for ruxolitinib expires in 2026. Extended protection through regulatory exclusivity or pediatric exclusivity may push full generic entry later in some jurisdictions. [1]

Can biosimilars enter before patent expiry?

Ruxolitinib is a small-molecule drug, not a biologic, so biosimilar pathways do not apply. Generic manufacturers must still respect active patents or wait for expiry before large-scale U.S. marketing.

Why are companies challenging this patent?

Paragraph IV certifications have been filed by multiple generic firms claiming either the 2026 composition patent or secondary patents are invalid or not infringed. Litigation between Incyte, Novartis, and challengers remains active.

What price range do current ruxolitinib suppliers offer?

Brand-name Jakafi lists at roughly $18,000 per month for a typical 20 mg twice-daily regimen. Generic versions from India are available through hospital channels or special-access programs and sell for 80–90% less than the branded price. [1]

Who makes ruxolitinib topical cream?

Incyte also owns the rights to Opzelura, a 1.5% ruxolitinib cream. Incyte handles manufacturing of the cream formulation for the U.S. market.